Trastuzumab pamirtecan (DB-1303/BNT323) in patients with previously treated HER2-expressing advanced/metastatic endometrial cancer: First global clinical phase 2 data

Gynecologic Oncology 2026

View at publisher
Authors: Bhavana Pothuri, Debra Richardson, Vicky Makker, Whitfield Growdon, Fernanda Musa, Oladapo Yeku, Hong Zheng, Michael Carney, Li Wang, Zifang Guo, Ji Hyun Lee, Nicole Lang
+9 more Claudia Gann, Michael Wenger, Hua Mu, Shengxue Liu, Yang Qiu, Jia Zhang, Rong Shi, Xiaohua Wu, Kathleen Moore
DOI: 10.1016/j.ygyno.2026.01.054
Cited by: 3

Fields of Study & Subjects

HER2/EGFR in Cancer Research Endometrial and Cervical Cancer Treatments PARP inhibition in cancer therapy

Publication details

Journal / source
Gynecologic Oncology
Publisher
Elsevier BV
Volume
208
Pages
S32–S32
Publication date
23 April 2026
Language
EN